Hansa Biopharma AB banner

Hansa Biopharma AB
SWB:24H

Watchlist Manager
Hansa Biopharma AB Logo
Hansa Biopharma AB
SWB:24H
Watchlist
Price: 2.27 EUR -9.05%
Market Cap: €263.7m

Wall St Price Targets

24H Price Targets Summary
Hansa Biopharma AB

Wall Street analysts forecast 24H stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 24H is 7.05 EUR with a low forecast of 3.26 EUR and a high forecast of 9.99 EUR.

Lowest Forecast
Price Target
3.26 EUR
44% Upside
Average Forecast
Price Target
7.05 EUR
211% Upside
Highest Forecast
Price Target
9.99 EUR
340% Upside
Hansa Biopharma AB Competitors:
Price Targets
VYNE
Vyne Therapeutics Inc
417% Upside
CASY
Caseys General Stores Inc
-11% Downside
HCAT
Health Catalyst Inc
38% Upside
MRVL
Marvell Technology Group Ltd
-22% Downside
PTCT
PTC Therapeutics Inc
37% Upside

Revenue
Forecast

41% / Year
Past Growth
51% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss
41% / Year
Past Growth
51% / Year
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 41%. The projected CAGR for the next 8 years is 51%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-58%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-58%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 24H's stock price target?
Price Target
7.05 EUR

According to Wall Street analysts, the average 1-year price target for 24H is 7.05 EUR with a low forecast of 3.26 EUR and a high forecast of 9.99 EUR.

What is the Revenue forecast for Hansa Biopharma AB?
Projected CAGR
51%

Over the last 13 years, the compound annual growth rate for Revenue has been 41%. The projected CAGR for the next 8 years is 51%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett